These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23314198)

  • 1. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
    Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
    Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
    Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
    Li SY; Wang W; Li JM; Wang Z; Wen RY; Chen J; Miao XT
    Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):605-8. PubMed ID: 22325221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
    Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
    Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
    Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
    Lai YL; Mau BL; Cheng WH; Chen HM; Chiu HH; Tzen CY
    Ann Surg Oncol; 2008 Apr; 15(4):1064-9. PubMed ID: 18183466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
    Buttitta F; Felicioni L; Barassi F; Martella C; Paolizzi D; Fresu G; Salvatore S; Cuccurullo F; Mezzetti A; Campani D; Marchetti A
    J Pathol; 2006 Feb; 208(3):350-5. PubMed ID: 16353168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of breast cancer axillary lymph node metastases with stem cell mutations.
    Donovan CA; Pommier RF; Schillace R; O'Neill S; Muller P; Alabran JL; Hansen JE; Murphy JA; Naik AM; Vetto JT; Pommier SJ
    JAMA Surg; 2013 Sep; 148(9):873-8. PubMed ID: 23884447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.
    Ang D; O'Gara R; Schilling A; Beadling C; Warrick A; Troxell ML; Corless CL
    J Mol Diagn; 2013 May; 15(3):312-8. PubMed ID: 23541593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
    Karakas B; Colak D; Kaya N; Ghebeh H; Al-Qasem A; Hendrayani F; Toulimat M; Al-Tweigeri T; Park BH; Aboussekhra A
    Cancer Biol Ther; 2013 Oct; 14(10):888-96. PubMed ID: 23982433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
    Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
    Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
    Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
    Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
    Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
    Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparison Between Full-COLD PCR/HRM and PCR Sequencing for Detection of Mutations in Exon 9 of PIK3CA in Breast Cancer Patients.
    Ghalamkari S; Khosravian F; Mianesaz H; Kazemi M; Behjati M; Hakimian SM; Salehi M
    Appl Biochem Biotechnol; 2019 Mar; 187(3):975-983. PubMed ID: 30109561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas.
    Lambert A; Salleron J; Lion M; Rouyer M; Lozano N; Leroux A; Merlin JL; Harlé A
    Pathol Oncol Res; 2019 Jul; 25(3):1117-1123. PubMed ID: 30426328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.